Tesamorelin: what it is, how it works, research, benefits and safety profile

Tesamorelin (tesamorelin) is a synthetic analogue of GHRH (Growth Hormone–Releasing Hormone), designed to stimulate endogenous secretion of growth hormone (GH) from the pituitary and to increase IGF-1. In clinical trials in adults with HIV-associated lipodystrophy significant reductions in visceral abdominal adipose tissue (VAT) and improvements in body composition have been shown. The information in this article is based on published scientific data and official prescribing information (see sources), as well as the summary on our product page. Studies on tesamorelin.

Tesamorelin: what it is, how it works, research, benefits and safety profile

Peptology · 2026-06-04

Tesamorelin (tesamorelin) is a synthetic analogue of GHRH (Growth Hormone–Releasing Hormone), designed to stimulate endogenous secretion of growth hormone (GH) from the pituitary and to increase IGF-1. In clinical trials in adults with HIV-associated lipodystrophy significant reductions in visceral abdominal adipose tissue (VAT) and improvements in body composition have been shown. The information in this article is based on published scientific data and official prescribing information (see sources), as well as the summary on our product page. Studies on tesamorelin.

What is tesamorelin?

Tesamorelin is a modified peptide analogue of natural GHRH. Unlike direct administration of GH, tesamorelin triggers pulsatile release of endogenous growth hormone, which is considered a more physiological approach to the GH–IGF-1 axis.

What it is studied for: In clinical trials, tesamorelin was studied for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for general weight loss. See more here: Tesamorelin - FDA Access Data

Mechanism of action: GH–IGF-1 axis

Receptor binding (GHRH-R) in the anterior pituitary
Pulsatile GH release (physiological dynamics)

Increase in IGF-1 → stimulation of lipolysis, tissue remodelling, metabolic effects
This sequential mechanism explains the reduction of visceral (not just subcutaneous) adipose tissue observed in studies. See more on the study of the effects of tesamorelin.

What the studies show (briefly)

Primary endpoints in RCTs: change in VAT and/or liver lipids; secondary – glycaemia and other metabolic markers. Several studies report significant reductions in VAT after 6–12 months of therapy.
There is also evidence for a modest reduction in liver lipids in some patients, including subgroups with fatty liver disease.

Tolerability: generally good; the most common events are injection site reactions, arthralgias, myalgias, peripheral oedema; changes in glucose metabolism and increases in IGF-1 are possible (monitoring required). Rarely reported – hypersensitivity, carpal tunnel syndrome, hyperglycaemia.

Benefits and applications of tesamorelin (research and clinical contexts)

Reduction of visceral adipose tissue and improved body composition in HIV-associated lipodystrophy.
Support of the GH–IGF-1 axis with potential benefits for recovery and metabolic profile (depending on model/population).
Liver metabolism: some studies report reductions in liver lipids/steatosis in certain groups.

See other peptides related to tesamorelin in our category "Peptides for recovery and anabolic".

Note: The product on Peptology is for research use only and is not a medicinal product. The information here is educational and summarises scientific data.

Safety profile of tesamorelin

Most common adverse reactions: local reactions (redness, pain, pruritus), arthralgia/myalgia, peripheral oedema. Increases in IGF-1 and disturbances in glycaemic control (observed in some studies; monitoring is recommended).

Contraindications and warnings (per prescribing information): active malignancy, pregnancy, hypersensitivity; not indicated for weight reduction outside the specific indication; long-term cardiovascular safety of the drug formulations remains unestablished.

Tesamorelin in the Peptology catalogue (research use)

On the product page you will find an overview of the mechanism, study summaries, frequently asked questions, as well as logistical information (delivery/storage). From there you can navigate to related GH-axis peptides (e.g. CJC-1295, Ipamorelin) to explore combination models.

Frequently asked questions

Tesamorelin and weight loss – are they the same?
No. The studied indication is HIV-associated lipodystrophy with excess abdominal fat, not general „weight loss“. FDA Access Data

How is it different from direct GH?
Tesamorelin is a GHRH analogue: it stimulates endogenous GH pulsatile release, rather than providing GH exogenously; this mimics the physiology of the GH–IGF-1 axis.

What are the most common adverse reactions?
Injection site reactions, arthralgia/myalgia, peripheral oedema; changes in glycaemia and increased IGF-1 are possible (monitoring advised).

Disclaimer

This material is for educational purposes only and does not constitute medical advice. Research products are not intended for human use.

Sources

FDA/Prescribing Information – tesamorelin – indication, contraindications, warnings, adverse reactions.
RCTs and clinical reviews for VAT/liver lipids: JAMA (2014); PubMed Central review of the same cohort; The Lancet HIV – effects on NAFLD in people with HIV.
LiverTox (NCBI Bookshelf) – safety profile, IGF-1 monitoring, rare risks. NCBI
Monographs/safety platforms – consolidated data on common adverse reactions and use limitations.